MARKET

SEPN

SEPN

Septerna, Inc.
NASDAQ
24.75
-0.09
-0.36%
After Hours: 24.75 0 0.00% 16:04 05/13 EDT
OPEN
24.50
PREV CLOSE
24.84
HIGH
25.48
LOW
24.24
VOLUME
315.74K
TURNOVER
--
52 WEEK HIGH
32.63
52 WEEK LOW
6.44
MARKET CAP
1.12B
P/E (TTM)
-22.4104
1D
5D
1M
3M
1Y
5Y
1D
Septerna Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 10h ago
HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target
Benzinga · 10h ago
Analysts Offer Insights on Technology Companies: Analog Devices (ADI), Septerna, Inc. (SEPN) and Zebra Tech (ZBRA)
TipRanks · 11h ago
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Circle Internet Group, Inc. Class A (CRCL) and Nvidia (NVDA)
TipRanks · 1d ago
Septerna Initiated with Buy Rating on Advancing GPCR Pipeline, Strong Early Data and Novo Nordisk Partnership Support
TipRanks · 1d ago
Septerna reports Q1 EPS (19c), consensus (27c)
TipRanks · 2d ago
Septerna, Inc. GAAP EPS of -$0.19 beats by $0.25, revenue of $26.52M beats by $11.43M
Seeking Alpha · 2d ago
Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration
Reuters · 2d ago
More
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

Webull offers Septerna, Inc. stock information, including NASDAQ: SEPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SEPN stock methods without spending real money on the virtual paper trading platform.